MoonLake Immunotherapeutics
MoonLake Immunotherapeutics (MLTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · MLTX · as of Sep 30, 2025
Ownership Breakdown
173
Institutional Holders
▲ 28 vs Q2
$490.93M
Total Inst. Value
▼ $2.27B vs Q2
73.62M
Shares Outstanding
freeFloat 85.86%
37.45M
13F Shares Held
▼ 21.13M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
MLTX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BVF INC/IL pharmaceutical preparations | 19.75M | 31.21% | 31.21% | $141.62B | Nov 14, 2025 | — held |
AVORO CAPITAL ADVISORS LLC pharmaceutical preparations | 2.00M | 3.16% | 3.16% | $14.34B | Nov 14, 2025 | ▼ 2.15M |
CORMORANT ASSET MANAGEMENT, LP pharmaceutical preparations | 1.99M | 3.15% | 3.15% | $14.30B | Nov 14, 2025 | ▼ 6.50M |
BALYASNY ASSET MANAGEMENT L.P. pharmaceutical preparations | 1.70M | 2.69% | 2.69% | $12.18B | Nov 14, 2025 | ▲ 1.28M |
ADAGE CAPITAL PARTNERS GP, L.L.C. pharmaceutical preparations | 1.50M | 2.37% | 2.37% | $10.76B | Nov 14, 2025 | NEW |
SCHONFELD STRATEGIC ADVISORS LLC pharmaceutical preparations | 965.4K | 1.53% | 1.53% | $6.92B | Nov 14, 2025 | ▲ 965.4K |
PRICE T ROWE ASSOCIATES INC /MD/ pharmaceutical preparations | 823.0K | 1.30% | 1.30% | $5.90B | Nov 14, 2025 | ▼ 1.79M |
JANE STREET GROUP, LLC pharmaceutical preparations | 812.7K | 1.28% | 1.28% | $5.83B | Nov 14, 2025 | ▲ 737.6K |
FMR LLC pharmaceutical preparations | 726.9K | 1.15% | 1.15% | $5.21B | Nov 13, 2025 | ▼ 5.00M |
NUVEEN, LLC pharmaceutical preparations | 635.7K | 1.00% | 1.00% | $4.56B | Nov 12, 2025 | ▼ 155.9K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
22
Increased
+7.06M shares13
New Positions
first time holders14
Decreased
−17.07M shares0
Sold Out
fully exitedNet shares change (top 50)
10.01M
+7.06M / −17.07M
Net new holders
+21
13 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
MLTX insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
6
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Bodenstedt Matthias Chief Financial Officer | May 11, 2026 | Sale | 13,653 | $20.02 | $273.3K | 1.17M | Form 4 ↗ |
Bodenstedt Matthias Chief Financial Officer | Apr 14, 2026 | Sale | 2,426 | $19.56 | $47.5K | 1.19M | Form 4 ↗ |
Santos da Silva Jorge Chief Executive Officer | Apr 10, 2026 | Sale | 98,127 | $18.41 | $1.81M | 2.98M | Form 4 ↗ |
Santos da Silva Jorge Chief Executive Officer | Apr 13, 2026 | Sale | 51,873 | $18.23 | $945.6K | 2.92M | Form 4 ↗ |
Bodenstedt Matthias Chief Financial Officer | Apr 9, 2026 | Sale | 85,870 | $18.94 | $1.63M | 1.19M | Form 4 ↗ |
Bodenstedt Matthias Chief Financial Officer | Apr 10, 2026 | Sale | 1,925 | $19.51 | $37.6K | 1.19M | Form 4 ↗ |
BVF PARTNERS L P/IL
| Mar 31, 2026 | Sale | 1,932,354 | $16.79 | $32.44M | 8.30M | Form 4 ↗ |
BVF PARTNERS L P/IL
| Mar 31, 2026 | Sale | 1,569,116 | $16.79 | $26.35M | 6.60M | Form 4 ↗ |
BVF PARTNERS L P/IL
| Mar 31, 2026 | Sale | 248,530 | $16.79 | $4.17M | 1.04M | Form 4 ↗ |
Bodenstedt Matthias Chief Financial Officer | Jan 7, 2026 | Award | 354,296 | — | — | 1.28M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
MoonLake Immunotherapeutics (MLTX) is primarily owned by institutional investors, who hold approximately 50.9% of total shares outstanding. Company insiders own approximately 14.14%, while retail and public investors account for the remaining 34.98%.
The largest institutional shareholder of MoonLake Immunotherapeutics is BVF INC/IL, holding approximately 19.75 million shares — equal to 31.21% of outstanding shares — as of September 30, 2025.
A total of 173 institutional investors currently hold MLTX stock, with a combined institutional value of approximately $490,929,242 as of the most recent 13F filing period.
Frequently asked questions
MLTX ownershipMoonLake Immunotherapeutics (MLTX) is primarily owned by institutional investors, who hold approximately 50.9% of shares. The largest shareholder is BVF INC/IL with a 31.21% stake. Company insiders hold 14.14%. Data sourced from SEC Form 13F as of September 30, 2025.